Oppenheimer initiated coverage on Vaxart with a new price target
$VXRT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/15/2024 | $4.00 | Outperform | Oppenheimer |
| 12/29/2021 | $13.00 → $12.00 | Buy | Jefferies |
| 11/2/2021 | $15.00 | Overweight | Cantor Fitzgerald |
| 6/30/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/29/2021 | $13.00 → $9.00 | Buy → Neutral | B. Riley Securities |
| 6/24/2021 | $13.00 | Buy | Jefferies |
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that members of the management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00 PM ET. A live webcast of the fireside chat will be available on the Company's website at www.vaxart.com or by clicking here. A replay of the fireside chat will be available for 30 days following the conclusion of the event. Investors interested in meeting with management during the conference may
Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" OR "Vaxart") today announces a video update for stockholders by Dr. Sean Tucker. The video is available on Vaxart's investor relations website at investors.vaxart.com. In the video, Dr. Tucker urges stockholders to vote FOR Proposal No. 2, which grants the Board of Directors authority to implement a reverse split that would enable Vaxart regain compli
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" OR "Vaxart") today answers additional frequently asked stockholder questions it has received from retail investors in advance of the Company's Annual Meeting of Stockholders scheduled to take place on Monday, June 2, 2025. "We appreciate the continued interest from our passionate and loyal stockholder base," said Steven Lo, Chief Executive Officer of Vaxart. "Understanding their concerns and directly addressing their most frequently asked questions, we are hopeful that thi
4 - Vaxart, Inc. (0000072444) (Issuer)
3 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
4 - Vaxart, Inc. (0000072444) (Issuer)
Oppenheimer initiated coverage of Vaxart with a rating of Outperform and set a new price target of $4.00
Jefferies resumed coverage of Vaxart with a rating of Buy and set a new price target of $12.00 from $13.00 previously
Cantor Fitzgerald initiated coverage of Vaxart with a rating of Overweight and set a new price target of $15.00
- Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced the appointment of Jeroen Grasman as its Chief Financial Officer (CFO), effective May 19, 2025. Mr. Grasman succeeds Phillip Lee, who is resigning from his position as CFO for personal reasons. To ensure a smooth transition, Mr. Lee will remain with the Company as a non-executive employee through June 1, 2025. "We are delighted to welcome Jeroen to the Vaxart team," said Steven Lo, Chief Executive Officer of Vaxart. "His extensive financial expertise and proven track record in the biotech sector, includ
Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced the appointment of Kevin Finney to the Company's Board of Directors, effective today. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise. Mr. Finney will serve as a member of the Audit and Nominating and Governance Committees of the Board. "Kevin adds a wealth of healthcare industry experience spanning executive leadership, governance, operations, and corporate deve
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) (the "Company" or "Vaxart") today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Ch
DEFA14A - Vaxart, Inc. (0000072444) (Filer)
PRE 14A - Vaxart, Inc. (0000072444) (Filer)
8-K - Vaxart, Inc. (0000072444) (Filer)
SC 13G/A - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)
SC 13G - Vaxart, Inc. (0000072444) (Subject)
Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company's second-generation oral norovirus vaccine constructs, with topline data expected in mid-2025 New avian influenza vaccine candidate was 100% protective in a ferret challenge model, compared with 0% survival in placebo-treated animals Jeroen Grasman appointed as Chief Financial Officer effective May 19, 2025 Cash, cash equivalents and investments of $41.9 million as of March 31, 2025; Current runway into 2026 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 13, 2025 (
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET. The conference call can be accessed using the following information: Webcast: Click hereDate: Tuesday, May 13, 2025 – 4:30 p.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13753354 Investors may submit written questions in advance of the confer
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents and investments of $51.7 million as of December 31, 2024 provides runway through multiple development milestones and into the fourth quarter of 2025 Conference call today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ:VXRT) today announced its business update and financial results for the full year 2024. "Since our founding, Vaxart has been on a mission to transform glo